Back to the Virtual Exhibit Hall



 Greg Romano

Oncology Account Manager







AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. In March 2021, AVEO received FDA approval of FOTIVDA® (tivozanib). To learn more about FOTIVDA, visit our website at

Website Link

Social Media Links








FOTIVDA® (tivozanib)

Power You Can Get Comfortable With

AVEO Access Center of Excellence

FOTIVDA® (tivozanib)

Power You Can Get Comfortable With

FOTIVDA 1.34 mg

Standard Dose Bottle

A comprehensive program dedicated to providing personalized support to patients and their loved ones throughout the FOTIVDA treatment Journey

Offer/Highlighted Product Link

AVEO ACE: Comprehensive Personalized Patient Support


FOTIVDA Patient Experience Program

Resources to Help with the Treatment Journey

Prescribing Information